

# Profile of Yeasts Isolated from Urinary Tracts of Catheterized Patients

MEENA MISHRA<sup>1</sup>, SEEMA AGRAWAL<sup>2</sup>, SHARMILA RAUT<sup>3</sup>, A. M. KURHADE<sup>4</sup>, R. M. POWAR<sup>5</sup>

## ABSTRACT

**Purpose:** Nosocomial fungal infections are important cause of morbidity and mortality in hospital patients. Urinary catheters have been held responsible to cause a large number of hospital acquired Urinary Tract Infections (UTIs). This study was undertaken to determine the incidence of nosocomial Candiduria associated with in dwelling urinary catheters, to characterize the species and assess their resistance to antifungal agents.

**Materials & Methods:** Urine specimens from 510 catheterized patients were inoculated on Sabouraud Dextrose Agar; the species identification of *Candida* isolates was done by biochemical tests and antifungal susceptibility testing was done by disc diffusion method.

**Results:** *Candida* was isolated in 112 (21.96%) specimens. Of these, *Candida albicans* was commonly isolated in 50.89%

followed by *C. tropicalis*, *C. glabrata*, *C. krusei*, *C. parapsilosis*, *C. guilliermondii* and *C. pseudotropicalis*. Fluconazole resistance was encountered in some isolates. All *C. glabrata* and *C. krusei* were uniformly resistant to fluconazole and 8 of 16 *C. tropicalis* were also resistant to it. But only 7 of 57 isolates of *C. albicans* were resistant to it. Resistance to Nystatin was seen in 34 isolates. Similarly, emergence of resistance was also seen to Ketoconazole and Itraconazole in 24 of 112 isolates. Amphoterecin B resistance was exhibited by 3 *C. albicans*, 2 *C. tropicalis*, 1 *C. glabrata* and 1 *C. krusei* strain. *C. albicans* is an important nosocomial pathogen causing UTI in catheterized patients, nevertheless role of other species of *Candida* as emergent pathogens and resistance to antifungal drugs needs to be emphasized.

**Keywords:** Yeasts, *Candida*, UTI, *C. albicans*

## INTRODUCTION

*Candida* UTIs are an increasingly prevalent nosocomial problem with uncertain significance [1] *Candiduria*, the presence of *Candida* species in the urine, is in most part associated with the use of urinary catheters [2]. The presence of *Candida* species in urine samples presents the physician with a challenge as to whether the candiduria represents colonization or, lower or upper UTI including ascending pyelonephritis and renal candidiasis with sepsis [3,4].

It is a difficult challenge to manage due to the fact that *Candida* species in the urine can be either completely insignificant or be a marker of a serious entity like renal parenchymal disease with other important clinical possibilities like *Candida* cystitis & fungal balls, that require specific treatment [5]. The surveillance data from the U. S. National Nosocomial surveillance system reported *Candida albicans* to be the fourth most common pathogen in UTI [6]. The data in this context from this region is rather fragmentary.

This study was designed to check prospectively the incidence of urinary catheter associated hospital candiduria and to evaluate the microbiological characteristics of the yeasts isolated from patients with indwelling urinary catheters.

## MATERIALS AND METHODS

Urine specimens were obtained from 510 catheterized patients, catheterized for at least for 72 hours, admitted in surgical (152), gynaecology (160) and Intensive Care Unit (ICU) (198), on two consecutive days. The second of the two samples was collected after half an hour of change of catheter. The catheter was clamped till the patient senses the urge to urinate or the bladder became palpable. The catheter port was cleaned with 70% alcohol and 10ml urine was collected using a needle and syringe [7].

The informed consent was obtained from the patients. The microscopy of the specimens was done. The specimens showing the presence of pus cells (above 5-7 pus cells/hpf) were included in the study. The specimens were plated on blood agar and Mac

Conkey agar for the isolation of bacteria.

The specimens were inoculated on two Sabouraud Dextrose agar slopes, one incubated at 37°C and other at room temperature.

The saline wet mounts were prepared from the growth to confirm that the colonies were of *candida* species.

*Candida* isolates which were culture positive on two occasions and negative for bacterial isolates were only subjected to further tests for identification of various species by Germ tube test, sugar fermentation, sugar assimilation and Corn Meal Tween 80 agar cut streak culture [8]. Sugar fermentation test was done using glucose @ sucrose, lactose, maltose, galactose and trehalose [9]. Sugar assimilation was done by auxanographic technique using yeast nitrogen base and various carbohydrate (glucose, galactose, sucrose, maltose, xylose and trehalose) impregnated discs [10]. *Candida albicans* assimilates glucose, galactose, sucrose, maltose, trehalose and xylose. *Candida tropicalis* assimilates glucose, galactose, sucrose, maltose, cellubiose, trehalose and xylose whereas *Candida glabrata* assimilates glucose and trehalose [10]. Chlamydiospore formation was studied by Corn Meal Tween 80 agar cut streak culture [8].

All the strains were tested for antifungal susceptibility testing by disc diffusion method [11] using discs (Hi-media) of Amphoterecin-B

Species	No. of Isolates (%)
<i>C. albicans</i>	57 (50.89%)
<i>C. tropicalis</i>	16 (14.29%)
<i>C. glabrata</i>	13 (11.61%)
<i>C. krusei</i>	8 (7.14%)
<i>C. parapsilosis</i>	7 (6.25%)
<i>C. guilliermondii</i>	7 (6.25%)
<i>C. kefyr</i>	4 (3.57%)
Total	112 (100%)

[Table/Fig-1]: Species distribution of candida isolates

Species (n)	FU (%)	NS (%)	KT (%)	IT (%)	AP (%)
<i>C. albicans</i> (57)	7 (12.28)	20 (35.09)	13 (22.81)	12 (21.05)	3 (5.26)
<i>C. tropicalis</i> (16)	8 (50.0)	6 (37.5)	4(25.0)	5 (31.25)	2 (12.5)
<i>C. glabrata</i> (13)	13 (100.0)	4 (30.77)	3 (23.08)	2 (15.39)	1 (7.69)
<i>C. krusei</i> (8)	8 (100.0)	2 (25.0)	2 (25.0)	3 (37.5)	1 (12.5)
<i>C. parapsilosis</i> (7)	0 (0.00)	0 (0.00)	1 (14.29)	1 (14.29)	0 (0.00)
<i>C. guilliermondii</i> (7)	0 (0.00)	1 (14.29)	0 (0.00)	1 (14.29)	0 (0.00)
<i>C. kefyr</i> (4)	0 (0.00)	1 (25.0)	1 (25.0)	0 (0.00)	0 (0.00)
Total (112)	36(32.14)	34(30.36)	24(21.43)	24(21.43)	07(6.25)

**[Table/Fig-2]:** Resistance pattern of candida to antifungal agents  
 FU: Fluconazole, NS: Nystatin, KT: Ketoconazole, IT: Itraconazole,  
 AP: Amphoterecin-B

(20µg), Fluconazole (25µg), Ketoconazole (30µg), Itraconazole (30µg), and Nystatin (50µg). The zone diameters were measured and interpreted as per the standard guidelines [11].

Results: Of the 510 patients, *Candida* species were present in 112 (21.96%) cases. It was present in 64 (28.70) out of 223 female patients and 48 (16.72%) out of 287 male patients. *Candida* species was isolated from 47 out of 198 (23.74%) ICU patients, 38 out of 160 (23.75%) patients of Gynaecology wards and 27 out of 152 (17.76%) surgical patients.

*C. albicans* was the commonest species (50.89%). But five other species viz *C. tropicalis*, *C. glabrata*, *C. krusei*, *C. parapsilosis*, *C. guilliermondii* and *C. kefyr* were also isolated.

The species distribution of *Candida* is shown in [Table/Fig-1].

The *Candida* isolates showed the resistance to antifungal agents. Their resistance profile is shown in [Table/Fig-2].

## DISCUSSION

*Candida* species isolation from urine cultures alone does not reveal the evidence of infection. The concept of hospital acquired candiduria involves the development of UTI caused by *Candida* species with a culture of > 10<sup>5</sup> CFU/ml on a specimen collected at least 72 hours after hospital admission and a previous *candida* species negative culture [12,13]. The presence of *candida* species was observed in 21.96% urine specimens from patients with urinary catheters. The isolation rates between 11 and 25.7% have been reported from different places [12,14,15]. *C. albicans* was more commonly reported in catheter-associated UTIs than in non-catheter-associated infections [16]. The *Candida* isolations were commonly seen in females as compared to males, which are in accordance to earlier reports [13,17]. The Candiduria was more common and almost at par in patients of Gynaecology wards and ICU as compared to surgical patients. In Gynaecology unit, all the patients were females in whom incidence is more for the reasons too well known [18] while in the other units patients with serious underlying illness with weakened defenses are admitted who as such need prolonged catheterization and hospital stay. The role of species other than *Candida albicans* as emergent pathogens of UTI have been well emphasized [17,19,20]. In the present study *C. albicans* (50.89%) was the most common isolate, followed *C. tropicalis* (14.29%), *C. glabrata* (11.61%) and other species as well. Earlier studies have also reported *C. albicans* to be most common isolate in UTI [21-24]. Although *C. albicans* continues to be the commonest, it must be emphasized that in almost half the cases other species of *Candida* are involved. Similar observations have been reported earlier too [24]. The other species can have more resistance to antifungal agents. The specific identification of candida species may also provide an important help in treatment choice, as *C. krusei* and *C. glabrata* are naturally resistant to fluconazole [25,26].

The sensitivity to *Candida* species to antifungal agents can be tested by a simple disc diffusion technique [27]. Resistant to various

antifungal agents have been well documented [27]. In the present study most of the strains were sensitive to Amphoterecin-B, where as varying degree of resistance was seen with other antifungal drugs tested, not only with *C. albicans* species, but also by other species. Fluconazole continues to be quite effective but emergence to resistance to it has been observed in the present study.

The *candida* species isolated in the present study may be considered as the causative agents due to the isolation of the same strain twice in the paired urine samples in absence of bacterial pathogens and in the light of microscopy of the urine deposit/sediment. The natural history of urinary tract colonization or infection due to *Candida* species in patients with indwelling urinary catheters has not been well defined [17,18]. Catheter removal and efficacy of antifungal drugs to eradicate *candida* from the urine has been clearly demonstrated [28].

## CONCLUSION

The data, in the present study, indicate that surveillance urine cultures for fungi should be carried out in patients with risk factors as they constitute one fifth of quantum of causative agents in such patients. Species identification is also important as about half of them are other than the *albicans* species and are likely to be more resistant. In view of emergence of drug resistance amongst the *candida* species, antifungal testing by a simple procedure of disc diffusion can be adopted to ascertain the choice of antifungal agents for therapy which are costly.

## REFERENCES

- Guler S, Ural O, Findik D, Arslan U. Risk factors for nosocomial candiduria. *Saudi Med J*. 2006;27(11):1706-10.
- Kauffman CA, Vazquez JD, Sobel JD, Gallis HA, McKinsey DS, Karchmer AW, et al. Prospective multicentre surveillance study of funguria in hospitalized patients. *Clin Infect Dis*. 2000; 30: 14-18.
- Kauffman CA. Candiduria. *Clin Infect Dis*. 2005;41(6):371-6.
- Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of candidiasis. *Clin Infect Dis*. 2004;38(2):161-9.
- Wise GJ., Goldberg P, Kozinn PJ. Genitourinary candidiasis: Diagnosis and treatment. *J. Urol*. 1976; 116:778-80.
- National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996. *Am J Infect*. 1996; 24: 380-88.
- Gilbert R. Obtaining a catheter specimen of urine. *Nursing Times*. 2006; 102(19): 22-23.
- Emmons CW, Binford CH, John P, Utz Kwon- Chung KJ. Candidiasis in Medical Mycology (Lea and Febiger) Philadelphia; 3rd Edition. 1977; 185-201.
- Collee JG, Fraser AG, Marmion BP, Simmons A (eds). Mackey & McCartney Practical Medical Microbiology. 14 ed. Edinburgh: Churchill Livingstone; 1996.
- Dolan CT. A practical Approach to Identification of Yeast-like organisms. *Am J Clin Pathol*. 1971;55(5): 580-90.
- Clinical Laboratory Standards Institution. Method for antifungal disk diffusion susceptibility testing of yeasts: Approved Guideline. Clinical Laboratory Standards Institution, 2008; M44-A2, Vol. 29, No. 17.
- Platt R, Polk BF, Murdock B, Rosner B. Reduction of mortality associated with nosocomial urinary-tract infection. *Lancet*. 1983;1(8330):893-97.
- Febre N, Silva V, Medeiros EAS, Wey SB, Colombo AL, Fischman O. Microbiological Characteristics of Yeasts Isolated from urinary tracts of Intensive Care Unit Patients undergoing urinary catheterization. *Journal of Clinical Microbiology*. 1999; 37(5): 1584-86.
- Hamory BH, Wenzel RP. Hospital associated candiduria: predisposing factors and review of the literature. *J.Urol*. 1978; 120: 444-48.
- Platt R, Murdock B, Rosner B. Mortality associated with nosocomial urinary tract infection. *N Engl J Med*. 1982; 11:637-42.
- Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in combined medical-surgical intensive care units in the United States. *Infect Control Hosp Epidemiol*. 2000; 21:510-15.
- Gubbins PO, Piscitelli SC, Danziger LH. *Candida* urinary tract infections: a comprehensive review of their diagnosis and management. *Pharmacotherapy*. 1993; 13: 110-27.
- Goldberg PK, Kozzin PJ, Wise GJ, Nouri N, Brooks RB. Frequency and significance of candiduria. *JAMA*. 1978; 24: 582-84.
- O'Connell, Harder CJ. Thrush of urinary bladder due to *Candida guilliermondii*. *J Med*. 1985. 73:1685-86.
- Pfaller M, Wenzel R. Impact of the changing epidemiology of fungal infections in the 1990s. *Eur J Clin Microbiol Infect Dis*. 1992; 11:287-91.
- Achkar JM and Fries CB. *Candida* infections of the Genitourinary Tract. *Clin Microbiol Rev*. 2010; 23(2): 253-73.
- Nayman AS, Ozgunes I, Ertem OT, Erben N, Doyuk KE, Tozun M, et al. Evaluation of risk factors in patients with candiduria. *Mikrobiyol Bul*. 2011; 45(2): 318-24.

- [23] Ece G, Samlioglu P, Akkoçlu G, Atalay S, Kose S. The evaluation of the distribution of yeast like fungi 'Candida species' at a tertiary care centre in western Turkey. *Int J Med Sci.* 2012; 9(7): 617-20.
- [24] Mohandas V and Ballal M. Distribution of *Candida* species in Different Clinical Samples and their Virulence: Biofilm Formation, Proteinase and Phospholipase Production: A Study on Hospitalized Patients in Southern India. *Glob Infect Dis.* 2011; 3(1): 4-8.
- [25] Odds FC. Resistance of yeast to azole- derivate antifungals. *J. Antimicrob. Chemother.* 1993; 31:46-71.
- [26] Rex JH, Rinaldi MG, Pfaller MA. Resistance of *Candida* species to fluconazole. *Antimicrob. Agents Chemother.* 1995; 39:1-8.
- [27] Inge Vandenbossche, Mario Vaneechoutte, Marleen V, Thierry De Baere, Gerda Verschraegen. Susceptibility Testing of Fluconazole by the NCCLS Broth Microdilution Method, E-Test, and Disk Diffusion for Application in the Routine Laboratory. *J Clin Microbiol.* 2002; 40(3):918-21.
- [28] Sobel JD, Kauffman CA, Mc Kinsey D, Zervos M, Vazquez JA, Karchmer J, et al. Candiduria: A randomized, double- blind study of treatment with fluconazole and placebo. *Clin Infect Dis.* 2000;30:19-24.

**PARTICULARS OF CONTRIBUTORS:**

1. Assistant Professor, Department of Microbiology, Government Medical College, Nagpur, Maharashtra, India.
2. Assistant Professor, Department of Microbiology, Government Medical College, Nagpur, Maharashtra, India.
3. Professor, Department of Microbiology, Government Medical College, Nagpur, Maharashtra, India.
4. Associate Professor, Department of Microbiology, Government Medical College, Nagpur, Maharashtra, India.
5. Dean, Department of Microbiology, Government Medical College, Nagpur, Maharashtra, India.

**NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:**

Dr. Meena Mishra,  
S-01, Shri Sunder Apts., Opp. Tb Wards, Rajabaxa Road, Wanzari Nagar, Nagpur-440 003, India.  
Phone: +91 9604327020, E-mail: meenarishika@yahoo.co.in

Date of Submission: **Jun 03, 2013**  
Date of Peer Review: **Sep 12, 2013**  
Date of Acceptance: **Dec 17, 2013**  
Date of Publishing: **Feb 03, 2014**

**FINANCIAL OR OTHER COMPETING INTERESTS:** None.